Presentations will highlight advancements in liquid biopsy, next-generation sequencing, and multi-omic approaches for cancer monitoring and biomarker detection.

Biodesix announced it will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 17 to 22, demonstrating capabilities in blood- and tissue-based testing and monitoring across various clinical applications.

The data to be presented cover research from basic science through clinical applications, including pre-validated assays for biopharmaceutical partners.

“The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts,” says Gary Pestano, PhD, chief scientific officer at Biodesix, in a release.

Tumor and Immune Profiling

The presentations highlight technology platforms such as mass spectrometry, Bio-Rad Droplet Digital PCR (ddPCR), and Thermo Fisher Ion AmpliSeq. Biodesix has also validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus System. This platform supports an automated clinical next-generation sequencing (NGS) workflow and can provide sequencing results in as little as 24 hours.

Specific sessions include a real-world analysis of non-small cell lung cancer (NSCLC) variant frequencies from liquid biopsy testing in diverse US populations. Another presentation will focus on a multiplexed ddPCR panel designed for sensitive NSCLC biomarker detection.

“The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR,” says Scott Hutton, CEO at Biodesix, in a release. “It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts.”

Molecular Residual Disease Pipeline

A series of presentations will focus on a multi-omic approach to molecular residual disease (MRD) monitoring. In collaboration with Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center, the company will present data on proteomic and genomic biomarkers and bioinformatics workflows.

One poster presentation will detail the “development of a comprehensive tumor-informed ctDNA workflow” for MRD detection using various tumor profiling inputs. Other research explores the detection of rare variants using a combination of genomic and proteomic applications for MRD monitoring.

The company will also present data on blood-based proteomic profiling to identify novel biomarkers of neuroendocrine prostate cancer. These advancements in the pipeline are reinforced by more than a decade of experience in the development and commercialization of new diagnostics, according to the company.

ID 440620808 © Kateryna Chyzhevska | Dreamstime.com

Related Reading: